Related Experiment Videos

Disseminated histoplasmosis in patients infected with human immunodeficiency virus

G A Sarosi1, P C Johnson

  • 1Department of Medicine, University of Arizona College of Medicine, Phoenix.

Insights

Progressive disseminated histoplasmosis (PDH) is a significant opportunistic infection in HIV patients. Early diagnosis and treatment with Amphotericin B, followed by suppressive therapy, are crucial for managing this severe fungal disease.

Area of Science:

  • Infectious Diseases
  • Mycology
  • Immunocompromised Hosts

Background:

  • Progressive disseminated histoplasmosis (PDH) is a common opportunistic infection in human immunodeficiency virus (HIV) patients.
  • PDH occurs in both endemic and nonendemic areas, often presenting as an AIDS-defining illness with systemic symptoms and potential respiratory involvement.

Purpose of the Study:

  • To highlight the diagnostic challenges and therapeutic strategies for progressive disseminated histoplasmosis in HIV-infected individuals.

Main Methods:

  • Review of clinical presentation, diagnostic modalities, and treatment outcomes for PDH in HIV.
  • Emphasis on diagnostic suspicion, blood cultures (lysis-centrifugation), bone marrow examination, respiratory secretions analysis.
  • Mention of an experimental histoplasma polysaccharide antigen serological test.

Main Results:

  • Chest roentgenograms may show diffuse infiltrates or be normal initially.
  • Timely diagnosis relies on a high index of suspicion and appropriate laboratory tests.
  • Amphotericin B is the primary treatment, with itraconazole showing promise for long-term suppression.

Conclusions:

  • PDH requires prompt diagnosis and aggressive management in HIV patients.
  • Diagnostic tools include cultures, smears, and antigen detection.
  • Amphotericin B followed by suppressive therapy is the recommended treatment approach.

Related Concept Videos